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A B S T R A C T
Background
Severe malaria kills over a million people every year. We sought evidence of superiority of artesunate compared with the standard
treatment quinine.
Objectives
To compare artesunate with quinine for treating severe malaria.
Search strategy
We searched the Cochrane Infectious Diseases Group Specialized Register (January 2007), CENTRAL (The Cochrane Library 2006,
Issue 4), MEDLINE (1966 to January 2007), EMBASE (1974 to January 2007), LILACS (1982 to January 2007), ISI Web of Science
(1945 to January 2007), the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles. We
contacted researchers and the World Health Organization.
Selection criteria
Randomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for
treating adults and children with severe malaria who are unable to take medication by mouth.
Data collection and analysis
Two authors assessed the eligibility and methodological quality of trials, extracted and analysed data, and drafted the review. The
third author contributed to the design and writing of the review. Death was the primary outcome. Dichotomous outcomes were
summarized using relative risks and continuous outcomes by mean differences.Where appropriate, we combined data in meta-analyses.
Heterogeneity was investigated for the primary outcome using subgroup analyses.
Main results
Six trials enrolling 1938 participants (1664 adults and 274 children) met our inclusion criteria. All six trials were conducted in Asia,
and only one small trial enrolled only children. Five trials used intravenous artesunate and one trial intramuscular artesunate; all
six used intravenous quinine. Treatment with artesunate significantly reduced the risk of death (RR 0.62, 95% CI 0.51 to 0.75;
1938 participants, 6 trials), reduced parasite clearance time (WMD 8.14 h, 95% CI 11.55 to 4.73; 292 participants, 3 trials), and
hypoglycaemia detected by routine monitoring (RR 0.46, 95% CI 0.25 to 0.87; 185 participants, 2 trials). There was no evidence of a
difference in neurological sequelae, coma recovery time, time to hospital discharge, fever clearance time, or adverse effects other than
hypoglycaemia.
Authors’ conclusions
Intravenous artesunate is the drug of choice for adults with severe malaria, particularly if acquired in Asia. This review did not identify
sufficient data to make firm conclusions about the treatment of children or the effectiveness of intramuscular artesunate. There is an
urgent need to compare the effects of artesunate with quinine in African children with severe malaria. The applicability of these results
to Asian children and the ethics of further research are points of debate.
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P L A I N L A N G U A G E S U M M A R Y
Artesunate reduces death from severe malaria in adults in Asia, but there is not enough evidence to say how effective artesunate
is in children, people in Africa, or on potential adverse effects
Severe malaria kills over a million people every year. The annual death toll can be as high as one in a 100 children under the age of five.
Severe malaria occurs when infection with the malaria parasite is complicated by serious failure of the body’s major organs. Sometimes
it is associated with coma (known as cerebral malaria). Following cerebral malaria a small proportion of children suffer with long-term
neurological disability.
Quinine, the standard treatment for severe malaria, often causes adverse effects. In most people symptoms are mild; less common but
more serious adverse effects include low blood sugar and heart rhythm disturbances. Regular glucose measurement and a heart trace
are therefore advised when quinine is given by injection. Lack of resources may not permit this monitoring in some settings.
Artesunate is generally well tolerated, safe, and does not require any monitoring. Artesunate comes from a family of drugs known as the
artemisinin derivatives. Another drug from this group, artemether, has shown no reduction in death compared to quinine. Artemether
absorption is erratic and unreliable. By contrast, artesunate levels peak reliably and predictably within an hour.
The review of trials assessed the effectiveness of artesunate versus quinine. Six trials involving 1938 people (1664 adults and 274
children) were identified, all undertaken in Asia. Treatment with artesunate significantly reduced the risk of death. It also reduced the
time taken to clear parasites from the blood and reduced the number of people with low blood sugar during follow up in trials where
this was routinely measured. There was no evidence to say if the drug is effective in children in Africa, in whom most deaths from
severe malaria occur.
B A C K G R O U N D
Severe malaria kills over a million people every year with annual
death rates of up to one in a 100 children under the age of five
(WHO 2000; Trape 2001). A small proportion of children may
also suffer from long-term neurological disability as a consequence
of severe malaria.
Severe malaria occurs when infection with the Plasmodium falci-
parum parasite is complicated by serious organ failure ormetabolic
abnormalities (Gilles 2000); cerebral malaria, unrousable coma
not attributable to any other cause, is a specific type of severe
malaria (Gilles 2000) that even with correct treatment can have a
mortality rate approaching 20% (Jaffar 1997). A small proportion
of survivors of cerebral malaria are left with persistent neurological
sequelae. Severe malaria occurs most commonly in those with lim-
ited immunity tomalaria. In highly endemic areas, young children
are therefore at most risk of severe disease and death, whereas in
areas of lower endemicity and travellers, both adults and children
get severe disease (White 2003).
The standard treatment for severe malaria is an intravenous infu-
sion of quinine (WHO 2000). Quinine may also be administered
as an intramuscular injection. A loading dose of 20 mg/kg is rec-
ommended to reduce the time needed to reach effective concen-
trations in the blood (White 1982). A Cochrane Review found a
significant reduction in fever clearance time and parasite clearance
time with a loading dose compared with no loading dose but con-
cluded that data were insufficient to demonstrate an impact on
risk of death (Lesi 2004).
Adverse effects resulting from quinine therapy are common. Cin-
chonism (symptoms of quinine overdose) often occurs at conven-
tional dose regimens. This usually mild and reversible symptom
complex consists of tinnitus, deafness, dizziness, and vomiting,
and may affect adherence. Hypoglycaemia is a less common but
more serious adverse effect (White 1983). Some people are al-
lergic to quinine and develop skin rashes and oedema even with
small doses. Toxic levels of quinine can occur following rapid in-
travenous administration and can result in heart rhythm distur-
bances, blindness, coma, and even death (Sweetman 2005); hence
the recommendation for routine cardiac monitoring during par-
enteral treatment (BNF 2007). In some parts of the world, such
as South-East Asia, there is limited evidence of declining efficacy
to quinine in severe malaria (Wongsrichanalai 2002).
Artesunate and other artemisinin derivatives offer an alternative to
quinine for severe malaria. Artemisinin derivatives are produced
from the leaves of the plant Artemesia annua and are less stage spe-
cific than quinine, killing young ring forms before sequestration
has occurred (ter Kuile 1993). Drugs from this group clear malaria
parasites faster than other agents, cure infections with multi-drug
resistant P. falciparum, and reduce gametocyte carriage, and thus
potentially the transmission (spread) of malaria (Adjuik 2004).
In contrast to quinine, administration of artemisinins does not
require cardiac monitoring and therefore may be a more practi-
cal option in resource-poor settings. Trials examining whether the
artemisinin derivative artemether is more effective than quinine
have not shown a reduction in mortality (AQMSG 2001). How-
ever, artemether, an oil-based intramuscular formulation, is prone
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to erratic and partial absorption (Karbwang 1997; Murphy 1997;
Mithwani 2003). In contrast, artesunate may be given by intra-
muscular or intravenous injection with peak concentrations reli-
ably achieved within one hour of administration (Nealon 2002;
Hien 2004).
Artemisinins are widely reported to be safe (Sweetman 2005). An-
imal studies using very high doses of artemisinins have demon-
strated focal brain stem lesions particularly affecting the audi-
tory pathways (Brewer 1994; Nontprasert 1998; Genovese 2000;
Nontprasert 2000;Nontprasert 2002).Many studies of brain stem
function inhumans, including audiometry, have failed to showany
abnormality following repeated courses of artemisinins (Ribeiro
1998; Kissinger 2000). To date, only one nested case-control study
has demonstrated a significant audiometric hearing loss in factory
workers treated with artemether-lumefantrine for uncomplicated
malaria compared with workers with no history of exposure to
malaria infection or artemether-lumefantrine (Toovey 2004). This
result needs to be interpreted with caution due to a number of
design limitations.
A Cochrane Review prepared in year 2000 assessed the effects
of the artemisinin derivatives, including artesunate, for treating
severe malaria (McIntosh 2000). This review has since been su-
perseded by a series of Cochrane Reviews examining the differ-
ent artemisinin derivatives, and our review concerns trials in arte-
sunate for severe malaria.
O B J E C T I V E S
To compare artesunate with quinine for treating severe malaria.
C R I T E R I A F O R C O N S I D E R I N G








Intravenous, intramuscular, or rectal artesunate.
Control
Intravenous or intramuscular quinine.





• Coma recovery time.
• Time to hospital discharge.
• Fever clearance time.
• Parasite clearance time.
Adverse effects
• Serious adverse effects resulting in discontinuation of treatment
(eg biochemical abnormalities, cardiac effects).
• Hypoglycaemia (symptomatic or asymptomatic).
• Other adverse events, including tinnitus, hearing impairment,
nausea, and vomiting.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Infectious Diseases Group methods used in
reviews.
We have attempted to identify all relevant trials regardless of
language or publication status (published, unpublished, in press,
and ongoing).
Databases
We searched the following databases using the search terms and
strategy described in Table 01: Cochrane Infectious Diseases
Group Specialized Register (January 2007); Cochrane Central
Register of Controlled Trials (CENTRAL), published in The
Cochrane Library (2006, Issue 4); MEDLINE (1966 to January
2007); EMBASE (1974 to January 2007); LILACS (1982 to
January 2007); ISI Web of Science (1945 to January 2007). We
also searched the metaRegister of Controlled trials (mRCT) using
artesunate and quinine as search terms.
Conference proceedings
We searched the following conference proceedings for relevant
abstracts: 4th Multilateral Initiative on Malaria (MIM) Pan-
African Malaria Conference, 13 to 18 November 2005, Yaoundé,
Cameroon; 4th European Congress on Tropical Medicine, 11
to 15 September 2005, Marseille, France; ACT NOW. An
International Symposium on Malaria, 29 to 30 April 2004,
Colombia, New York, USA; 2nd International Malaria Research
Conference, John Hopkins Malaria Research Institute, 25
to 26 March 2004, Maryland, USA; 3rd MIM Pan-African
Conference, 18 to 22 November 2002, Arusha, Tanzania; and the
3rd European Congress on Tropical Medicine and International
Health, 8 to 12 September 2002, Lisbon, Portugal.
Researchers, organizations, and pharmaceutical companies
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We contacted individual researchers working in the field and the
World Health Organization for unpublished and ongoing trials
in January 2006.
Reference lists
We checked the reference lists of existing reviews and of all trials
identified by the above methods.
M E T H O D S O F T H E R E V I E W
Study selection
All trials identified by the search strategy were screened by
Katharine Jones (KJ) and Sarah Donegan (SD) and full reports of
potentially relevant trials were obtained. KJ and SD independently
applied the inclusion criteria to the full reports using an eligibility
form and scrutinized publications to ensure each trial was
included in the review only once. Trial authors were contacted for
clarification if necessary. Disagreement was resolved by discussion
with David Lalloo (DL).
Assessment of methodological quality
KJ and SD independently evaluated the methodological quality
of each trial and recorded the results in a table. The generation of
the allocation sequence and allocation concealment were classified
as adequate, inadequate, or unclear according to Juni 2001.
Descriptive datawere collected onwhether participants, providers,
and outcome assessors were blind to the treatment given. Inclusion
of all randomizedparticipants (proportionof participants included
for which an efficacy endpoint is available) was classified as
adequate (if > 90%), inadequate (if ≤ 90%), or unclear. Trial
authors were contacted for clarification if necessary. Disagreement
was resolved by discussion with the third author.
Data extraction
KJ and SD independently extracted data using a data extraction
form. For each outcome we aimed to extract the number
of participants randomized and the number analysed in each
treatment group. For dichotomous outcomes, we recorded the
number of participants experiencing the event and the number
assessed in each treatment group. For continuous outcomes,
we extracted arithmetic means and standard deviations for each
treatment group, together with the numbers assessed in each
group. Ifmedians had been usedwe also extracted ranges whenever
it was possible.
Data analysis
We analysed the data with Review Manager 4.2 (RevMan) using
relative risk (RR) for dichotomous data, weightedmean difference
(WMD) for continuous data, and 95% confidence intervals (CI).
Medians and ranges were reported in a table. If arithmetic means
were reported, normality of the data was checked by calculating
the ratio of the mean over the standard deviation (Altman 1996).
If this test suggested the data were skewed (ie if the ratio was less
than 2), we commented on this in the text but still combined the
results in a meta-analysis.
If there was discrepancy between the number randomized and the
number analysed, we calculated the percentage loss to followup for
each treatment group and reported this information. Originally,
we aimed to analyse data according to the intention-to-treat
principle (all randomized participants should be analysed in the
groups to which they were originally assigned). However, since for
some trials it was unclear whether there was loss to follow up, we
entered the number analysed into RevMan whenever these figures
were available. By attempting to carry out a complete-case analysis
in this way, we have tried to avoid making assumptions about the
outcomes of participants that were lost to follow up.
We looked for statistical heterogeneity by inspecting the forest
plots for overlapping confidence intervals, applying the chi-
squared test (P-value < 0.10 considered statistically significant),
and the I2 test (I2 value of 50% used to denote moderate levels
of heterogeneity). If heterogeneity was detected but it was still
considered clinically meaningful to combine studies, a random-
effects model was used. The potential sources of heterogeneity
explored for the primary outcome measure were prespecified in
the protocol or post-hoc. The prespecified sources were allocation
concealment, blinding, participant age (children versus adults),
and drug regimen (loading dose versus no loading dose of
quinine and use of any additional antimalarials). The post-hoc
sources were presentation of severe malaria (severe versus cerebral
malaria), method of diagnosing malaria (blood film versus rapid
diagnostic test), route of artesunate administration (intravenous
versus intramuscular), time since admission to hospital (before and
after 48 hours since admission), and hyperparasitaemia.
As only one small trial used intramuscular artesunate we presented
these results as a subgroup analysis rather than pooling data
according to route of administration as stated in the protocol.
We constructed funnel plots to look for evidence of publication
bias. The small number of trials included in the meta-analyses
precluded meaningful use of these plots.
D E S C R I P T I O N O F S T U D I E S
The six trials thatmet our inclusion criteria enrolled a total of 1938
participants of which 1664 were adults and 274 were children.
Only one trial enrolled only children (Cao 1997); this small trial
included 72 children. Results for children in the other trials could
not be separated out for analysis (see ’Characteristics of included
studies’). We identified one ongoing study, a large multicentre
trial in African children (see ’Characteristics of ongoing studies’).
Thirteen trials detected by the search specifications were excluded
from the review (see ’Characteristics of excluded studies’).
Location
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Four trials took place in single centres in Vietnam. The other two
weremulticentred:Newton2003had two centres inThailand; and
Dondorp 2005 had 11 centres throughout Bangladesh, Myanmar,
India, and Indonesia.
Source of funding
Three trials were funded by a medical research charity, one by in-
ternational organizations including the World Health Organiza-
tion, and one, Anh 1989, had contributions in the form of the
study drugs from pharmaceutical companies. Funding was not
specified for one trial (Hien 1992).
Participants
Anh 1989, Hien 1992, and Anh 1995 enrolled only adults with
cerebral malaria; Cao 1997 included only children with cerebral
malaria; Newton 2003 included only adults with severe malaria;
and Dondorp 2005 included both adults and children with severe
malaria. All trials except Dondorp 2005 used the presence of P.
falciparum parasitaemia to confirm the diagnosis of malaria. Don-
dorp 2005 used a positive rapid diagnostic test. Although stan-
dardized clinical definitions for severe malaria exist, entry criteria
were not consistent across trials
Interventions
All trials compared artesunate with quinine. Artesunate was given
intravenously in five trials and intramuscularly in one trial (Cao
1997). Quinine was given intravenously in all six trials with an
initial loading dose in four of these. Drug dosage and duration
of treatment varied between the trials (see ’Characteristics of in-
cluded studies’ for details). Five trials gave an additional oral an-
timalarial to at least one of the treatment arms, which was un-
matched between the treatment arms. Two trials, Hien 1992 and
Cao 1997, included an additional rectal artemisinin arm that was
not pertinent to this review.
Supportive care
All six trials reported measuring blood glucose on admission, but
only four trials reported any subsequent monitoring for hypogly-
caemia. Three trials reported routine measurement of blood glu-
cose at variable time intervals; monitoring of all participants sev-
eral times a day (Newton 2003); monitoring of all participants
every four hours for the first 24 hours and then every six hours in
any participants with coma, prostration, jaundice, or more than
one complication (Cao 1997); monitoring in all participants on
days 1, 3, 7, and 14 (Anh 1989). Blood glucose was only measured
in those participants with clinical signs of hypoglycaemia in one
trial (Dondorp 2005).
Outcome measures (defined in Table 02)
All six trials reported death as an outcome. Two trials reported
neurological sequelae at discharge (Cao 1997; Dondorp 2005).
Five trials reported coma recovery time (Anh 1989; Hien 1992;
Anh 1995; Cao 1997; Newton 2003), and four trials reported
fever clearance time (Hien 1992; Anh 1995; Cao 1997; Newton
2003). Reporting of parasite clearance time varied between trials
and included parasite clearance times of 50%, 90%, 95%, and
100%. We chose to include data for parasite clearance time of
50% as this was most frequently reported in the trials (Anh 1989;
Hien 1992; Anh 1995; Cao 1997; Newton 2003). Three trials
reported time to hospital discharge (Cao 1997; Newton 2003;
Dondorp 2005). Three trials reported adverse effects including
hypoglycaemia (Cao 1997; Newton 2003; Dondorp 2005).
Length of follow up
Cao 1997 specified that participants were asked to return for a
follow up visit three weeks after discharge from hospital. None of
the other trials reported the length of follow up.
M E T H O D O L O G I C A L Q U A L I T Y
See Table 03 for a summary of the assessment of trial method-
ological quality. Further details are located in the ’Characteristics
of included studies’.
The generation of the allocation sequence was adequate in all six
trials. Allocation concealment was adequate in four trials; Anh
1989 and Newton 2003 reported that the randomization was
open. In all six trials, investigators were aware of treatment allo-
cation. Participants were blind to the intervention in Hien 1992,
and microscopists and data analysts were blind to the interven-
tion in Dondorp 2005. Newton 2003 and Dondorp 2005 clearly
stated that no participants were lost to follow up. We were able
to obtain individual patient data for one trial in which primary
outcomes available for all included participants (Cao 1997). The
number of participants randomized was used in the analysis for
the remaining three trials (Anh 1989; Hien 1992; Anh 1995).
R E S U L T S
Death
Death was reported in all six trials. Treatment with artesunate sig-
nificantly reduced the risk of death (RR 0.62, 95% CI 0.51 to
0.75; 1938 participants, 6 trials, Analysis 01.01) with a consis-
tent reduction across trials. A subgroup analyses of trials reporting
mortality before and after 48 hours since admission to hospital
found no difference between the groups within 48 hours (1646
participants, 3 trials, Analysis 01.02).
In view of significant variation in trial design we explored potential
sources of heterogeneity for mortality. We found that excluding
trialswith inadequate allocation concealment (Analysis 01.03), tri-
als in which all participants had cerebral malaria (Analysis 01.04),
and those with no loading dose of quinine (Analysis 01.05) did
not alter the significance of the result. The one trial in which all
participants were children found no evidence of a difference be-
tween the artesunate and quinine (72 participants, 1 trial, Analy-
ses 01.06). This small trial was also the only trial to use an intra-
muscular formulation of artesunate (Analyses 01.07). Only one
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trial looked at the effect of hyperparasitaemia on death (Dondorp
2005). It found that artesunate was more effective than quinine
only in those participants with hyperparasitaemia (RR 0.26, 95%
CI 0.14 to 0.49; 229 participants, 1 trial), with no evidence of a
difference in those participants with no hyperparasitaemia (1153
participants, 1 trial). This result needs to be interpreted with cau-
tion as these subgroups may not be truly randomized.
Neurological sequelae at discharge
Two trials reported results for this outcome (Cao 1997; Dondorp
2005), and they found no evidence of a difference between the
groups (1253 participants, 2 trials, Analysis 01.08).
Coma recovery time
The three trials that reported median coma recovery time had in-
consistent results (see Table 04). Frequency of measuring this out-
come varied between the trials (see Table 02). Two trials reported
mean coma recovery time (Anh 1989; Anh 1995). There was no
evidence of a difference between the groups, although the data
were skewed and the results were inconsistent (231 participants, 2
trials, Analysis 01.09). One trial reported the mean, median, and
mode for this outcome (Hien 1992), and the difference between
these results suggest the data are skewed.
Time to hospital discharge
Two trials reported this outcome as amedian (Cao 1997;Dondorp
2005). The results were consistent and showed no evidence of a
difference between the groups (see Table 04). One trial reported
this outcome as a mean (Newton 2003) with no evidence of a
difference between the groups (113 participants, 1 trial, Analysis
01.10). The data appear skewed.
Fever clearance time
Two trials reported this outcome as a mean (Hien 1992; Anh
1995). There was no evidence of a difference between the groups,
although the data appeared to be skewed and the results incon-
sistent (251 participants, 2 trials, Analysis 01.11). Two trials re-
ported this outcome as a median (Cao 1997; Newton 2003), and
the results were inconsistent (see Table 04). The frequency with
which this outcome was measured differed between the trials (see
Table 02).
Parasite clearance time
Three trials reported parasite clearance time of 50% as a mean
(Anh 1989; Hien 1992; Anh 1995). Treatment with artesunate
was associated with a reduction in parasite clearance time in all
three trials (WMD 8.14 h, 95% CI 11.55 to 4.73; 292 partici-
pants, 3 trials, Analysis 01.12). Two trials reportedmedian parasite
clearance times of 50% (Newton 2003; Cao 1997), and the results
were inconsistent (see Table 04). The frequency with which this
outcome was measured differed between the trials (see Table 02).
Adverse effects
No trial reported discontinuation of medication. With the excep-
tion of hypoglycaemia, all adverse effects reported could be at-
tributable to malaria. Artesunate was associated with less hypogly-
caemia after admission, both in the two trials that measured blood
glucose routinely (RR 0.46, 95% CI 0.25 to 0.87; 185 partici-
pants, 2 trials, Analysis 01.13.01) and in the one trial that only
measured this outcome in participants with clinical signs of hy-
poglycaemia (RR 0.32, 95% CI 0.13 to 0.79; 1461 participants,
1 trial, Analysis 01.13.02).
D I S C U S S I O N
Treatment with artesunate resulted in a significant reduction in
mortality, parasite clearance time, and hypoglycaemia in people
with severe malaria in Asia. There was no evidence of a difference
in coma recovery time, time to hospital discharge, fever clearance
time, or adverse effects other than hypoglycaemia. The number
of participants with neurological sequelae is too small to draw
any conclusions from these data. Subgroup analyses showed that
the beneficial effect of artesunate was most marked in preventing
death after 48 hours and occurred in cerebral malaria as well as all
categories of severe malaria. One trial suggests that the benefit of
artesunate is even greater in people with hyperparasitaemia.
Interpretation of these results is complicated by a number of dif-
ferent factors. The most important of these is that all of the trials
were conducted in Asia and that most of the participants were
adults. The biology and epidemiology of severe malaria is differ-
ent in children who tend to present with a more severe spectrum
of disease. It is therefore difficult to extrapolate these findings to
African children who have the highest burden of severe disease.
Differing quinine sensitivity patterns in South-East Asiamaymean
the magnitude of the beneficial effect of artesunate may not be as
great in other parts of the world.
A wide variation in trial design also complicates interpretation of
these results. Subgroup analyses showed that excluding poor qual-
ity trials, trials with no loading dose of quinine, and those in which
all participants had cerebral malaria did not alter the reduction
in mortality. Five out of six trials administered unmatched addi-
tional oral antimalarials to the intervention and control group,
introducing a possible source of confounding factors. The trials
also varied in their vigilance for hypoglycaemia, an important and
reversible cause of death in patients with severe malaria, and which
occurred with lower frequency in the artesunate arms. This could
impair the ability of trials to quantify the benefits of artesunate as
an antimalarial.
Despite these comments, the beneficial effect of intravenous arte-
sunate upon mortality was considerable, and this is a very im-
portant intervention to improve the outcome in this major dis-
ease. Intramuscular artesunate would be particularly appropriate
for resource-poor settings, but there were insufficient data for this
review to establish the effectiveness of this formulation compared
to quinine.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Intravenous artesunate is the drug of choice for adults with severe
malaria, particularly if acquired in Asia. This review did not iden-
tify sufficient data to make firm conclusions about the treatment
of children or the effectiveness of intramuscular artesunate. This
review highlights the inadequate routine measurement of blood
glucose, which ideally should be checked several times a day as ad-
vocated by recent World Health Organization guidelines (WHO
2006).
Implications for research
This reviewhighlights a number of areas requiring further research.
In particular, there is an urgent need to establish the compara-
tive effectiveness of artesunate and quinine for severe malaria in
African children. The ongoing study identified by this review has
been designed to answer both this question as well as the relative
effectiveness of intramuscular artesunate in this group. The appli-
cability of these results to Asian children and the ethics of further
research are points of debate. This review provides limited infor-
mation regarding differences in hypoglycaemia and neurological
sequelae between the two treatments, which impairs the ability to
quantify the benefits of artesunate as an antimalarial. Both these
outcomes are important in severe malaria, and future trials should
include routine monitoring of blood glucose and prolonged neu-
rological follow up for all participants.
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T A B L E S
Characteristics of included studies
Study Anh 1989
Methods Generation of allocation sequence: random-number tables (personal communication from author)
Allocation concealment: open
Blinding: open label
Inclusion of all randomized participants: not reported
Participants Number: 41 enrolled
Inclusion criteria: adults > 16 yr old with cerebral malaria (P. falciparum parasitaemia > 1000/mm3 and
Glasgow Coma Scale of 14 or less not attributable to any cause other than malaria)
Exclusions: not specified
Interventions 1. Artesunate: 60 mg IV at 0, 4, 24, and 48 h
2. Quinine: 20 mg/kg IV loading dose over 4 h at 0 h then 10 mg/kg IV every 8 h until able to swallow then
10 mg/kg PO every 8 h until day 7
Outcomes 1. Death
2. Coma recovery time
3. Parasite clearance time of 50%
Not included in the review:
4. Parasite clearance time of 95%
Notes Location: Vietnamese hospital
Transmission: not specified
Date: February to December 1989
Funding: Roche Asian Research Foundation supplied artesunate (personal communication from author)
Additional antimalarials: none
Allocation concealment B – Unclear
Study Anh 1995
Methods Generation of allocation sequence: central randomization (personal communication from author)
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Characteristics of included studies (Continued )
Allocation concealment: sealed envelopes (personal communication from author)
Blinding: open label
Inclusion of all randomized participants: not reported
Participants Number: 190 enrolled
Inclusion criteria: adults 15 to 65 yr with cerebral malaria (asexual P. falciparum parasitaemia and clinical
signs of cerebral malaria alone or associated with other visceral complications)
Exclusion criteria: associated P. vivax parasitaemia, pregnancy, and concomitant diseases such as diabetes
mellitus, stroke, meningitis, head trauma, pulmonary tuberculosis, or AIDS
Interventions 1. Artesunate: 60 mg IV at 0, 4, 24, and 48 h
2. Quinine: 10 mg/kg IV over 4 h at 0 h then 10 mg/kg IV every 8 h until able to swallow then quinine PO
at similar doses every 8 h until day 7
Outcomes 1. Death within 24 h
2. Death after 24 h
3. Coma recovery time
4. Fever clearance time
5. Parasite clearance time of 50%
Not included in the review:
6. Parasite clearance time of 95%
7. Parasite clearance time of 100%
8. Time to sit
9. Time to take oral by self medication
Notes Location: Vietnamese clinical research centre
Transmission: not specified
Date: July 1992 to May 1995
Funding: World Health Organization
Additional antimalarials: artesunate given mefloquine PO 15 mg/kg at day 7; quinine none
Allocation concealment A – Adequate
Study Cao 1997
Methods Generation of allocation sequence: computer generated (personal communication from author)
Allocation concealment: sealed envelopes
Blinding: open label
Inclusion of all randomized participants: 100% (personal communication from author)
Participants Number: 72 enrolled
Inclusion criteria: children < 15 yr with severe malaria (asexual P. falciparum parasitaemia plus at least 1 of
the following: coma (Blantyre Coma Scale less than or equal to 3), severe anaemia (capillary haematocrit <
15%) with parasitaemia (> 10,000/µL); hyperparasitaemia (> 10% parasitized red blood cells or parasitaemia
> 500,000/µL); jaundice (obvious clinically or serum bilirubin > 48 µmol/L); hypoglycaemia (blood glucose
< 2.2 mmol/L); spontaneous bleeding (eg gastrointestinal haemorrhage); shock (systolic blood pressure < 50
mmHg if aged < 6 yr, or < 70 mmHg if aged 6 to 14 yr); repeated generalized convulsions (3 or more in
24 h despite cooling); renal impairment (serum creatinine > 177 µmol/L, or urine output < 12 mL/kg/24 h
that fails to improve despite rehydration)
Exclusion criteria: severe diarrhoea, mixed infection with P. vivax, prior treatment with quinine > 60 mg/kg,
artemisinin > 20 mg/kg, or artesunate > 2 mg/kg during the illness episode, or any antimalarial treatment
continuing for > 48 h
Interventions 1. Artesunate: 3 mg/kg IM at 0 h then 2 mg/kg IM at 12, 24, 48, and 72 h
2. Quinine: 20 mg/kg IV loading dose over 4 h (omitted if pretreatment with quinine) then 10 mg/kg IV
every 8 h up to day 7
3. [Not relevant to review: rectal artemisinin]
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Characteristics of included studies (Continued )
Outcomes 1. Death
2. Number survived with neurological sequelae
3. Fever clearance time (all patients, excluding superinfections)
4. Coma resolution
5. Parasite clearance time of 50%
6. Period in hospital
7. Hypoglycaemia
8. Adverse effects
Not included in this review:
9. Number survived well
10. Time to death from admission
11. Parasite clearance time of 90%
12. Parasite clearance time of 100%
13. Number with acute renal failure
14. Shock
15. Convulsions




20. Urinary tract infection
21. Other infection
22. Reticulocyte count at admission, on day 5, at discharge
23. Haematocrit at admission, on day 5, at discharge
Notes Location: Vietnamese hospital
Transmission: not specified
Date: August 1992 to March 1995
Funding: Wellcome Trust of Great Britain
Additional antimalarials given: artesunate arm received mefloquine PO 15 mg/kg at 96 h; quinine arm given
sulfadoxine-pyrimethamine 500 mg/25 mg on day 7
Allocation concealment A – Adequate
Study Dondorp 2005
Methods Generation of allocation sequence: computer generated
Allocation concealment: sealed envelopes
Blinding: open label; the trial centre, microscopists assessing blood slides, and data analysts were blinded
Inclusion of all randomized participants: 100%
Participants Number: 1461 enrolled
Inclusion criteria: adults and children > 2 yr with severe malaria (positive blood antigen stick test for P.
falciparum and a diagnosis of severe malaria, according to the admitting physician)
Exclusion criteria: convincing history of full treatment with quinine (40 mg/kg on the first day and 30 mg/kg
on any subsequent day) or an artemisinin derivative for more than 24 h before admission, known allergy to
1 of the artemisinin derivatives or quinine
Interventions 1. Artesunate: 2.4 mg/kg IV at 0, 12, and 24 h then 2.4 mg/kg IV every 24 h until able to swallow then PO
2 mg/kg until day 7
2. Quinine: 20 mg/kg IV loading dose then 10 mg/kg every 8 h until able to swallow then PO 10 mg/kg
every 8 h until day 7
Outcomes 1. In-hospital death
2. Death within 48 h of entry
3. Death after 48 h of entry
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Characteristics of included studies (Continued )
4. In-hospital death (blood-smear positive)
5. Neurological sequelae
6. Time to discharge (median, IQR, and range)
7. Hypoglycaemia after entry
Not included in the review:
8. Combined outcome: in hospital death or neurological sequelae
9. Fetal death
10. Time to speak (median, IQR, and range)
11. Time to eat (median, IQR, and range)
12. Time to sit (median, IQR, and range)
13. Convulsions after entry
14. Shock developing after entry
15. Blackwater fever developing after entry
16. Dialysis after entry
17. Vasopressor treatment after entry
18. Mechanical ventilation after entry
Notes Location: hospitals in Bangladesh, Myanmar, India, and Indonesia
Transmission: not specified
Date: June 2003 to May 2005
Funding: Wellcome Trust grant
Additional antimalarials: both arms except in India and Bangladesh were given doxycycline (100 mg every
12 h for 7 d) once able to swallow
Allocation concealment A – Adequate
Study Hien 1992
Methods Generation of allocation sequence: randomization tables (personal communication from author)
Allocation concealment: sealed envelopes
Blinding: participant blinded
Inclusion of all randomized participants: not reported
Participants Number: 61 enrolled
Inclusion criteria: cerebral malaria (P. falciparum parasitaemia with clinical signs of malaria and a Glasgow
Coma Scale < 10)
Exclusion criteria: not specified
Interventions 1. Artesunate: 60 mg IV at 0, 4, 24, and 48 h
2. Quinine: 500 mg IV over 4 h then 500 mg IV every 8 h until able to swallow then 500 mg PO every 8 h
until day 14
3. [Not relevant to review: rectal artemisinin]
Outcomes 1. Fever clearance time
2. Parasite clearance time of 50%
3. Time to regain full consciousness
4. Death
Not included in the review:
5. Parasite clearance time of 90%
6. Parasite clearance time of 100%
Notes Location: intensive care unit in Vietnam
Transmission: not specified
Date: 1989 to 1990
Funding: artesunate was provided by Professor Li Guo Qiao
Additional antimalarials: artesunate arm had mefloquine (PO 500 mg) once able to swallow
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Allocation concealment A – Adequate
Study Newton 2003
Methods Generation of allocation sequence: computer generated
Allocation concealment: open randomization
Blinding: open label
Inclusion of all randomized participants: 100%
Participants Number: 113 enrolled, 100 analysed
Inclusion criteria: adults aged 15 yr or above with severe malaria (single-species P. falciparum parasitaemia >
0.1% plus at least 1 of following: Glasgow Coma Scale < 11; haematocrit < 20% with asexual parasitaemia
> 100,000/µL; total serum bilirubin > 50 µmol/L with asexual parasitaemia > 100,000/µL; serum creatinine
> 264 mol/µL with urine output < 400 mL/24 h; systolic blood pressure < 80 mmHg with cool extremities;
asexual parasitaemia > 10%; plasma lactate level > 4 mmol/L; plasma glucose level < 2.2 mmol/L; plasma
venous bicarbonate level < 15 mmol/L
Exclusion criteria: pregnancy, contraindications to study drugs, artesunate, mefloquine, or significant quinine
(> 2 g) intake in the previous 24 h
Interventions 1. Artesunate: 2.4 mg/kg IV at 0 h then 1.2 mg/kg at 12 h then 1.2 mg/kg every 24 h until able to swallow
then 12 mg/kg PO every 24 h over 7 days
2. Quinine: 20 mg/kg IV over 4 h loading dose then 10 mg/kg IV every 8 until able to swallow then 10
mg/kg PO until day 7
Outcomes 1. Fever clearance time
2. Parasite clearance time of 50%




Not included in the review:
7. Parasite clearance time of 90%
8. Parasite clearance time of 100%
Notes Location: 2 hospitals in Thailand
Transmission: seasonal low intensity
Date: May to July 1994 and 1995 to 2001
Funding: Wellcome Trust of Great Britain
Additional antimalarials: once able to swallow some participants in both arms were given additional anti-
malarials, but the drug given varied during the trial; AS: no additional antimalarial (n = 22), mefloquine 15
mg/kg (n = 1), mefloquine 25 mg/kg in 2 doses (n = 22), doxycycline 100 mg every 12 h for 7 d (n = 14);
quinine: no additional antimalarial (n = 20), tetracycline 250 mg every 12 h for 7 d (n = 19), doxycycline
100 mg every 12 h for 7 days (n = 15)
Allocation concealment C – Inadequate
IM: intramuscular; IQR: intraquartile range; IV: intravenous; n: number of participants; P.: Plasmodium; PO: by mouth
Characteristics of excluded studies
Study Reason for exclusion
Awad 2003 Not a randomized controlled trial
Barnes 2004 Not severe malaria
Bounyasong 2001 Not severe malaria
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Characteristics of excluded studies (Continued )
Haroon 2005 A quasi-randomized controlled trial in which the first patient was allocated a treatment at random and then
future patients were allocated their treament using an alternating pattern
Krudsood 2003 Not a randomized controlled trial
Li 1990 Not severe malaria
McGready 2001a Not severe malaria
McGready 2001b Not a randomized controlled trial
Mohanty 2004 Not a randomized controlled trial (quasi-randomized)
Newton 2001 Treatment comparison is artesunate versus artesunate and quinine
Pukrittayakamee 2004 Not severe malaria
Win 1992 Not a randomized controlled trial
Zhao 2001 Not severe malaria
Characteristics of ongoing studies
Study AQUAMAT
Trial name or title “The AQUAMAT trial: An open label randomised comparison of injectable artesunate and quinine in children
with severe falciparum malaria in Africa”
Participants Inclusion criteria: OptiMal malaria rapid test positive; and treating physician considers patient to have severe
malaria
Exclusion criteria: patient has received more than or equal to 24 h of effective treatment with quinine or an
artemisinin derivative; or patient has known allergy to quinine or an artemisinin derivative
Interventions 1. Intramuscular artesunate versus intramuscular quinine
2. Intravenous artesunate versus intravenous quinine
Outcomes 1. In-hospital mortality
2. Neurological sequelae
3. Recovery times
Starting date 18 July 2005






Design: open, randomized, multicentre trial
Location: Mozambique, Kenya, Gambia, Ghana
Target recruitment number: 5300
End of recruitment date: 31 December 2005
End of follow-up date: 31 April 2009
15Artesunate versus quinine for treating severe malaria (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
A D D I T I O N A L T A B L E S
Table 01. Detailed search strategies
Search set CIDG SRˆ CENTRAL MEDLINEˆˆ EMBASEˆˆ LILACSˆˆ
ISI Web of
Science
1 malaria malaria malaria malaria malaria malaria
2 quinine quinine quinine quinine quinine quinine








5 3 or 4 2 or 3 or 4 2 or 3 or 4 2 or 3 or 4 3 or 4 3 or 4
6 1 and 2 and 5 artesunate artesunate artesunate 1 and 2 and 5 1 and 2 and 5
7 - arsumax arsumax arsumax - -
8 - 6 or 7 6 or 7 6 or 7 - -
9 - 1 and 5 and 8 1 and 5 and 8 1 and 5 and 8 - -


















case: free text term
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Table 02. Definitions of outcome measures used in the review
Trial Death Neuro. sequelaeˆ
Coma recovery
time Time to discharge
Fever clearance
time PCT 50%ˆˆ Hypoglycaemia Adverse effects
Anh 1989 Death Not reported Mean value (h)
reported but not
defined




every 8 h until 2
consecutive slides
were negative and
then every 24 h
Not reported Not reported















Not reported Mean value (h)
reported. Defined













every 4 h for 12
h, then every 6 h
until 3 consecutive
films were negative
Not reported None reported

























Not reported Not reported







































































































Table 02. Definitions of outcome measures used in the review (Continued )
Trial Death Neuro. sequelaeˆ
Coma recovery
time Time to discharge
Fever clearance











before onset of the
episode of malaria















4 h (or more
frequently if
critically ill) for
the first 24 h, and





°C or below and
remained below
this level for at
least 24 h. Axillary
temperature
measured every
4 h (or more
frequently if
critically ill) for
the first 24 h, and




every 4 h (or
more frequently if
critically ill) for
the first 24 h, and












4 h for first 24 h
























Newton 2003 Death Not reported Median value (h)
reported. Defined
as time to reach a
Glasgow Coma
Scale of 15 in those
participants with




every 15 min for
first h, at 2 h, and



















0, 1, 2, 4, 6, 8, 10,
12, 16, 20, and 24
h, and then every
6 h until 6 h after
parasite clearance
Plasma glucose
less than or equal
to 2.2 mmol/L.
Plasma glucose
measured at 0, 4,
8, 12, 16, 20, and


































































































Table 02. Definitions of outcome measures used in the review (Continued )
Trial Death Neuro. sequelaeˆ
Coma recovery
time Time to discharge
Fever clearance
time PCT 50%ˆˆ Hypoglycaemia Adverse effects
then every 2 h
until 12 h, every 4
h from 12 to 24 h,
and every 6 h from
24 h until the
score reached 15
min for the first h,
at 2 h, and then
every 2 h until 12
h, every 4 h from
12 to 24 h, and
every 6 h from
24 h until fever
cleared




Not reported Median value (d)
reported








































































































Table 03. Assessment of methodological quality
Trial Randomizationˆ Concealmentˆ Blinding Inclusionˆ
Anh 1989 Adequate Inadequate Open label Unclear
Hien 1992 Adequate Adequate Participant blinded Unclear
Anh 1995 Adequate Adequate Open label Unclear
Cao 1997 Adequate Adequate Open label Adequate (100%)
Newton 2003 Adequate Inadequate Open label Adequate (100%)
Dondorp 2005 Adequate Adequate Open label (trial centre,
microscopists assessing blood slides,
and data analysts blinded until trial
end)
Adequate (100%)
ˆGeneration of allocation sequence,
allocation concealment, and
inclusion of all randomized
participants
Table 04. Time-to-event data: medians, ranges, and modes
Outcome Trial Artesunate Quinine
Coma recovery time (h): median
(range), number
Hien 1992 35 (5 to 453); mode = 17; mean =
68.9
48 (7 to 144), mode = 43; mean =
58.1
Cao 1997 42 (4 to 228), n = 10 31 (4 to 66), n = 2
Newton 2003 17 (1 to 125), n = 16 18 (1 to 188), n = 16
Time to hospital discharge (d):
median (range), number
Cao 1997 8 (5 to 20), n = 33 8 (5 to 24), n = 29
Dondorp 2005 5 (0 to 54), n = 623 5 (0 to 45), n = 567
Fever clearance time (until first
below 37.5 °C) (h): median (range),
number
Cao 1997 4 (4 to 198), n = 35 8 (0 to 96), n = 35
Newton 2003 11 (1 to 83), n = 42 13 (1 to 184), n = 42
Fever clearance time (until remains
below 37.5 °C for 24 h) (h): median
(range), number
Cao 1997 84 (4 to 198), n = 35 81 (0 to 246), n = 30
Newton 2003 41 (3 to 138), n = 32 65 (12 to 383), n = 27
Time to parasite clearance of 50%
(h): median (range), number
Cao 1997 5.7 (2.0 to 15.3), n = 35 13.2 (2.4 to 103.0), n = 32
Newton 2003 9.1 (0.3 to 37.2), n = 56 8.0 (0.2 to 46.0), n = 49
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A N A L Y S E S





participants Statistical method Effect size
01 Death 6 1938 Relative Risk (Fixed) 95% CI 0.62 [0.51, 0.75]
02 Death: time since admission to
hospital [subgroup analysis]
6 3292 Relative Risk (Fixed) 95% CI 0.65 [0.52, 0.81]
03 Death: allocation concealment
[subgroup analysis]
6 1938 Relative Risk (Fixed) 95% CI 0.62 [0.51, 0.75]
04 Death: cerebral malaria
[subgroup analysis]
6 1938 Relative Risk (Fixed) 95% CI 0.62 [0.51, 0.75]
05 Death: loading dose vs no
loading dose of quinine
[subgroup analysis]
6 1938 Relative Risk (Fixed) 95% CI 0.62 [0.51, 0.75]
06 Death: participant age
[subgroup analysis]
6 1938 Relative Risk (Fixed) 95% CI 0.62 [0.51, 0.75]
07 Death: intravenous vs
intramuscular artesunate
[subgroup analysis]
6 1938 Relative Risk (Fixed) 95% CI 0.62 [0.51, 0.75]
08 Neurological sequelae at
discharge
2 1253 Relative Risk (Fixed) 95% CI 2.21 [0.64, 7.63]
09 Coma recovery time 2 231 Weighted Mean Difference (Random) 95% CI 2.11 [-19.17, 23.40]
10 Time to hospital discharge Weighted Mean Difference (Fixed) 95% CI Totals not selected
11 Fever clearance time 2 251 Weighted Mean Difference (Random) 95% CI -13.58 [-55.09,
27.92]
12 Parasite clearance time of 50% 3 292 Weighted Mean Difference (Random) 95% CI -8.14 [-11.55, -4.73]
13 Hypoglycaemia Relative Risk (Fixed) 95% CI Subtotals only
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimalarials [administration & dosage; ∗therapeutic use]; Artemisinins [administration & dosage; ∗therapeutic use]; Injections,
Intramuscular; Injections, Intravenous; Malaria [∗drug therapy; mortality]; Quinine [administration & dosage; ∗therapeutic use];
Randomized Controlled Trials as Topic; Sesquiterpenes [administration & dosage; ∗therapeutic use]
MeSH check words
Adult; Child; Humans
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Artesunate vs quinine, Outcome 01 Death
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 01 Death
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Anh 1989 2/19 7/22 3.0 0.33 [ 0.08, 1.41 ]
Anh 1995 8/99 18/91 8.7 0.41 [ 0.19, 0.89 ]
Cao 1997 4/37 5/35 2.4 0.76 [ 0.22, 2.59 ]
Dondorp 2005 107/730 164/731 76.3 0.65 [ 0.52, 0.81 ]
Hien 1992 5/31 8/30 3.8 0.60 [ 0.22, 1.64 ]
Newton 2003 7/59 12/54 5.8 0.53 [ 0.23, 1.26 ]
Total (95% CI) 975 963 100.0 0.62 [ 0.51, 0.75 ]
Total events: 133 (Artesunate), 214 (Quinine)
Test for heterogeneity chi-square=2.26 df=5 p=0.81 I² =0.0%
Test for overall effect z=4.82 p<0.00001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
Analysis 01.02. Comparison 01 Artesunate vs quinine, Outcome 02 Death: time since admission to hospital
[subgroup analysis]
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 02 Death: time since admission to hospital [subgroup analysis]
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Death within 48 h
Cao 1997 3/37 3/35 1.7 0.95 [ 0.20, 4.38 ]
Dondorp 2005 61/730 75/731 41.3 0.81 [ 0.59, 1.12 ]
Newton 2003 4/59 9/54 5.2 0.41 [ 0.13, 1.24 ]
Subtotal (95% CI) 826 820 48.2 0.78 [ 0.57, 1.05 ]
Total events: 68 (Artesunate), 87 (Quinine)
Test for heterogeneity chi-square=1.43 df=2 p=0.49 I² =0.0%
Test for overall effect z=1.65 p=0.1
02 Death after 48 h
Cao 1997 1/37 2/35 1.1 0.47 [ 0.04, 4.99 ]
0.01 0.1 1 10 100
Favours artesunate Favours quinine (Continued . . . )
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(. . . Continued)
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Dondorp 2005 46/730 89/731 49.0 0.52 [ 0.37, 0.73 ]
Newton 2003 3/59 3/54 1.7 0.92 [ 0.19, 4.34 ]
Subtotal (95% CI) 826 820 51.8 0.53 [ 0.38, 0.74 ]
Total events: 50 (Artesunate), 94 (Quinine)
Test for heterogeneity chi-square=0.50 df=2 p=0.78 I² =0.0%
Test for overall effect z=3.78 p=0.0002
Total (95% CI) 1652 1640 100.0 0.65 [ 0.52, 0.81 ]
Total events: 118 (Artesunate), 181 (Quinine)
Test for heterogeneity chi-square=4.76 df=5 p=0.45 I² =0.0%
Test for overall effect z=3.84 p=0.0001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
Analysis 01.03. Comparison 01 Artesunate vs quinine, Outcome 03 Death: allocation concealment [subgroup
analysis]
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 03 Death: allocation concealment [subgroup analysis]
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Adequate allocation concealment
Anh 1995 8/99 18/91 8.7 0.41 [ 0.19, 0.89 ]
Cao 1997 4/37 5/35 2.4 0.76 [ 0.22, 2.59 ]
Dondorp 2005 107/730 164/731 76.3 0.65 [ 0.52, 0.81 ]
Hien 1992 5/31 8/30 3.8 0.60 [ 0.22, 1.64 ]
Subtotal (95% CI) 897 887 91.2 0.63 [ 0.51, 0.77 ]
Total events: 124 (Artesunate), 195 (Quinine)
Test for heterogeneity chi-square=1.37 df=3 p=0.71 I² =0.0%
Test for overall effect z=4.41 p=0.00001
02 Inadequate allocation concealment
Anh 1989 2/19 7/22 3.0 0.33 [ 0.08, 1.41 ]
Newton 2003 7/59 12/54 5.8 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 78 76 8.8 0.46 [ 0.22, 0.97 ]
Total events: 9 (Artesunate), 19 (Quinine)
Test for heterogeneity chi-square=0.31 df=1 p=0.58 I² =0.0%
0.01 0.1 1 10 100
Favours artesunate Favours quinine (Continued . . . )
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(. . . Continued)
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Test for overall effect z=2.05 p=0.04
Total (95% CI) 975 963 100.0 0.62 [ 0.51, 0.75 ]
Total events: 133 (Artesunate), 214 (Quinine)
Test for heterogeneity chi-square=2.26 df=5 p=0.81 I² =0.0%
Test for overall effect z=4.82 p<0.00001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
Analysis 01.04. Comparison 01 Artesunate vs quinine, Outcome 04 Death: cerebral malaria [subgroup
analysis]
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 04 Death: cerebral malaria [subgroup analysis]
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 All participants have cerebral malaria
Anh 1989 2/19 7/22 3.0 0.33 [ 0.08, 1.41 ]
Anh 1995 8/99 18/91 8.7 0.41 [ 0.19, 0.89 ]
Hien 1992 5/31 8/30 3.8 0.60 [ 0.22, 1.64 ]
Subtotal (95% CI) 149 143 15.5 0.44 [ 0.25, 0.78 ]
Total events: 15 (Artesunate), 33 (Quinine)
Test for heterogeneity chi-square=0.57 df=2 p=0.75 I² =0.0%
Test for overall effect z=2.84 p=0.005
02 Severe malaria
Cao 1997 4/37 5/35 2.4 0.76 [ 0.22, 2.59 ]
Dondorp 2005 107/730 164/731 76.3 0.65 [ 0.52, 0.81 ]
Newton 2003 7/59 12/54 5.8 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 826 820 84.5 0.65 [ 0.52, 0.80 ]
Total events: 118 (Artesunate), 181 (Quinine)
Test for heterogeneity chi-square=0.26 df=2 p=0.88 I² =0.0%
Test for overall effect z=4.04 p=0.00005
Total (95% CI) 975 963 100.0 0.62 [ 0.51, 0.75 ]
Total events: 133 (Artesunate), 214 (Quinine)
Test for heterogeneity chi-square=2.26 df=5 p=0.81 I² =0.0%
Test for overall effect z=4.82 p<0.00001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
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Analysis 01.05. Comparison 01 Artesunate vs quinine, Outcome 05 Death: loading dose vs no loading dose of
quinine [subgroup analysis]
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 05 Death: loading dose vs no loading dose of quinine [subgroup analysis]
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 No loading dose
Anh 1995 8/99 18/91 8.7 0.41 [ 0.19, 0.89 ]
Hien 1992 5/31 8/30 3.8 0.60 [ 0.22, 1.64 ]
Subtotal (95% CI) 130 121 12.5 0.47 [ 0.25, 0.87 ]
Total events: 13 (Artesunate), 26 (Quinine)
Test for heterogeneity chi-square=0.37 df=1 p=0.54 I² =0.0%
Test for overall effect z=2.42 p=0.02
02 Loading dose
Anh 1989 2/19 7/22 3.0 0.33 [ 0.08, 1.41 ]
Cao 1997 4/37 5/35 2.4 0.76 [ 0.22, 2.59 ]
Dondorp 2005 107/730 164/731 76.3 0.65 [ 0.52, 0.81 ]
Newton 2003 7/59 12/54 5.8 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 845 842 87.5 0.64 [ 0.52, 0.78 ]
Total events: 120 (Artesunate), 188 (Quinine)
Test for heterogeneity chi-square=1.08 df=3 p=0.78 I² =0.0%
Test for overall effect z=4.24 p=0.00002
Total (95% CI) 975 963 100.0 0.62 [ 0.51, 0.75 ]
Total events: 133 (Artesunate), 214 (Quinine)
Test for heterogeneity chi-square=2.26 df=5 p=0.81 I² =0.0%
Test for overall effect z=4.82 p<0.00001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
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Analysis 01.06. Comparison 01 Artesunate vs quinine, Outcome 06 Death: participant age [subgroup
analysis]
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 06 Death: participant age [subgroup analysis]
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Adults (15/16 years +)
Anh 1989 2/19 7/22 3.0 0.33 [ 0.08, 1.41 ]
Anh 1995 8/99 18/91 8.7 0.41 [ 0.19, 0.89 ]
Hien 1992 5/31 8/30 3.8 0.60 [ 0.22, 1.64 ]
Newton 2003 7/59 12/54 5.8 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 208 197 21.4 0.47 [ 0.29, 0.75 ]
Total events: 22 (Artesunate), 45 (Quinine)
Test for heterogeneity chi-square=0.68 df=3 p=0.88 I² =0.0%
Test for overall effect z=3.17 p=0.002
02 Children 2 to 15 years
Cao 1997 4/37 5/35 2.4 0.76 [ 0.22, 2.59 ]
Subtotal (95% CI) 37 35 2.4 0.76 [ 0.22, 2.59 ]
Total events: 4 (Artesunate), 5 (Quinine)
Test for heterogeneity: not applicable
Test for overall effect z=0.44 p=0.7
03 All ages
Dondorp 2005 107/730 164/731 76.3 0.65 [ 0.52, 0.81 ]
Subtotal (95% CI) 730 731 76.3 0.65 [ 0.52, 0.81 ]
Total events: 107 (Artesunate), 164 (Quinine)
Test for heterogeneity: not applicable
Test for overall effect z=3.78 p=0.0002
Total (95% CI) 975 963 100.0 0.62 [ 0.51, 0.75 ]
Total events: 133 (Artesunate), 214 (Quinine)
Test for heterogeneity chi-square=2.26 df=5 p=0.81 I² =0.0%
Test for overall effect z=4.82 p<0.00001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
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Analysis 01.07. Comparison 01 Artesunate vs quinine, Outcome 07 Death: intravenous vs intramuscular
artesunate [subgroup analysis]
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 07 Death: intravenous vs intramuscular artesunate [subgroup analysis]
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Intravenous artesunate
Anh 1989 2/19 7/22 3.0 0.33 [ 0.08, 1.41 ]
Anh 1995 8/99 18/91 8.7 0.41 [ 0.19, 0.89 ]
Dondorp 2005 107/730 164/731 76.3 0.65 [ 0.52, 0.81 ]
Hien 1992 5/31 8/30 3.8 0.60 [ 0.22, 1.64 ]
Newton 2003 7/59 12/54 5.8 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 938 928 97.6 0.61 [ 0.50, 0.75 ]
Total events: 129 (Artesunate), 209 (Quinine)
Test for heterogeneity chi-square=2.15 df=4 p=0.71 I² =0.0%
Test for overall effect z=4.81 p<0.00001
02 Intramuscular artesunate
Cao 1997 4/37 5/35 2.4 0.76 [ 0.22, 2.59 ]
Subtotal (95% CI) 37 35 2.4 0.76 [ 0.22, 2.59 ]
Total events: 4 (Artesunate), 5 (Quinine)
Test for heterogeneity: not applicable
Test for overall effect z=0.44 p=0.7
Total (95% CI) 975 963 100.0 0.62 [ 0.51, 0.75 ]
Total events: 133 (Artesunate), 214 (Quinine)
Test for heterogeneity chi-square=2.26 df=5 p=0.81 I² =0.0%
Test for overall effect z=4.82 p<0.00001
0.01 0.1 1 10 100
Favours artesunate Favours quinine
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Analysis 01.08. Comparison 01 Artesunate vs quinine, Outcome 08 Neurological sequelae at discharge
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 08 Neurological sequelae at discharge
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Cao 1997 1/33 0/30 14.3 2.74 [ 0.12, 64.69 ]
Dondorp 2005 7/623 3/567 85.7 2.12 [ 0.55, 8.17 ]
Total (95% CI) 656 597 100.0 2.21 [ 0.64, 7.63 ]
Total events: 8 (Artesunate), 3 (Quinine)
Test for heterogeneity chi-square=0.02 df=1 p=0.89 I² =0.0%
Test for overall effect z=1.26 p=0.2
0.01 0.1 1 10 100
Favours artesunate Favours quinine
Analysis 01.09. Comparison 01 Artesunate vs quinine, Outcome 09 Coma recovery time
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 09 Coma recovery time
Study Artesunate Quinine Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Anh 1989 19 45.17 (30.29) 22 53.60 (25.87) 51.5 -8.43 [ -25.82, 8.96 ]
Anh 1995 99 71.30 (81.00) 91 58.00 (49.00) 48.5 13.30 [ -5.57, 32.17 ]
Total (95% CI) 118 113 100.0 2.11 [ -19.17, 23.40 ]
Test for heterogeneity chi-square=2.76 df=1 p=0.10 I² =63.7%
Test for overall effect z=0.19 p=0.8
-100.0 -50.0 0 50.0 100.0
Favours artesunate Favours quinine
Analysis 01.10. Comparison 01 Artesunate vs quinine, Outcome 10 Time to hospital discharge
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 10 Time to hospital discharge
Study Artesunate Quinine Weighted Mean Difference (Fixed) Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI 95% CI
Newton 2003 59 5.10 (3.14) 54 5.00 (4.50) 0.10 [ -1.34, 1.54 ]
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Analysis 01.11. Comparison 01 Artesunate vs quinine, Outcome 11 Fever clearance time
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 11 Fever clearance time
Study Artesunate Quinine Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Anh 1995 99 67.36 (41.40) 91 63.30 (46.50) 59.0 4.06 [ -8.50, 16.62 ]
Hien 1992 31 39.00 (30.00) 30 78.00 (102.00) 41.0 -39.00 [ -77.00, -1.00 ]
Total (95% CI) 130 121 100.0 -13.58 [ -55.09, 27.92 ]
Test for heterogeneity chi-square=4.45 df=1 p=0.03 I² =77.5%
Test for overall effect z=0.64 p=0.5
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Analysis 01.12. Comparison 01 Artesunate vs quinine, Outcome 12 Parasite clearance time of 50%
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 12 Parasite clearance time of 50%
Study Artesunate Quinine Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Anh 1989 19 7.58 (3.32) 22 15.73 (9.78) 30.0 -8.15 [ -12.50, -3.80 ]
Anh 1995 99 10.64 (8.24) 91 16.12 (14.25) 37.5 -5.48 [ -8.83, -2.13 ]
Hien 1992 31 5.40 (3.20) 30 16.60 (10.70) 32.5 -11.20 [ -15.19, -7.21 ]
Total (95% CI) 149 143 100.0 -8.14 [ -11.55, -4.73 ]
Test for heterogeneity chi-square=4.65 df=2 p=0.10 I² =57.0%
Test for overall effect z=4.68 p<0.00001
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Analysis 01.13. Comparison 01 Artesunate vs quinine, Outcome 13 Hypoglycaemia
Review: Artesunate versus quinine for treating severe malaria
Comparison: 01 Artesunate vs quinine
Outcome: 13 Hypoglycaemia
Study Artesunate Quinine Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
01 Routine monitoring
Cao 1997 6/37 9/35 37.1 0.63 [ 0.25, 1.59 ]
Newton 2003 6/59 15/54 62.9 0.37 [ 0.15, 0.88 ]
Subtotal (95% CI) 96 89 100.0 0.46 [ 0.25, 0.87 ]
Total events: 12 (Artesunate), 24 (Quinine)
Test for heterogeneity chi-square=0.71 df=1 p=0.40 I² =0.0%
Test for overall effect z=2.39 p=0.02
02 Clinical monitoring
Dondorp 2005 6/730 19/731 100.0 0.32 [ 0.13, 0.79 ]
Subtotal (95% CI) 730 731 100.0 0.32 [ 0.13, 0.79 ]
Total events: 6 (Artesunate), 19 (Quinine)
Test for heterogeneity: not applicable
Test for overall effect z=2.47 p=0.01
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